Orion Oyj
ORION CORPORATION NOTICE TO ANNUAL GENERAL MEETING/STOCK EXCHANGE RELEASE 3 MARCH 2021 at 11.30 EET
Change to the Notice of Orion Corporation’s Annual General Meeting
The Board of Directors of Orion Corporation has decided to change the venue of Orion Corporation’s Annual General Meeting 2021 and accordingly the notice to the Annual General Meeting so that the meeting is held at Orion Corporation's Head Office, Orionintie 1, Espoo, instead of Hotel Kämp. In other respects, the notice to the Annual General Meeting published on 9 February 2021 is unchanged and the change of venue does not affect the registrations already made or the advance votes cast. The notice to the Annual General Meeting is available on Orion's website at www.orion.fi/en.
Shareholders can participate in the meeting and exercise their shareholder rights either by themselves or by proxy representation only by voting in advance and by making counterproposals and presenting questions in advance in accordance with the notice to the Annual General Meeting and the Company’s other instructions. It is not possible to participate in the Annual General Meeting at the meeting venue.
Shareholders can follow the Annual General Meeting over the internet via a video stream. Following the meeting over the internet via the video stream is not considered participation in the Annual General Meeting. Instructions for shareholders to participate in the Annual General Meeting as well as to follow the meeting over the internet via the video stream are presented in the notice to the Annual General Meeting.
Orion Corporation
Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Olli Huotari, SVP, Corporate Functions
tel. +358 10 426 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Bitget Limited12.7.2025 07:17:59 CEST | Press release
Bitget Launchpool to List Chainbase (C) with 2.75M in Token Rewards
Ingredion Incorporated11.7.2025 22:03:00 CEST | Press release
Ingredion to Release 2025 Second Quarter Financial Results On August 1, 2025
Strategic Partners A/S11.7.2025 21:58:13 CEST | Pressemeddelelse
Ledende medarbejders transaktion
Brookfield Corporation11.7.2025 19:45:09 CEST | Press release
Brookfield Corporation to Host Second Quarter 2025 Results Conference Call
Bang & Olufsen A/S11.7.2025 18:37:35 CEST | Press release
Long Term Share-based incentive programme for 2025/26
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom